In this study, the anti-herpetic activities of novel 2'methyl nucleoside analogues which were substituted at the 5 position of the pyrimidine with a halogen were investigated. The 2'-fluoro-5-iodo-aracytosine (FIAC) congeners (2'S)-2'·deoxy-2'-G-methylcytidine which were substituted with Br or I at the 5 position (SMBC or SMIC); and 2'-fluoro-5-iodo-arauridine (FIAU) congeners (2'S)-2'-deoxy-2'-G-methyluridine which were substituted with Br or I at the 5 position (SMBU or SMIU), proved to have potent antiviral activities against herpes simplex virus type-1 (HSV-1) and varicella-zoster virus (VZV) but not against herpes simplex virus type -2 (HSV-2).
The nucleoside analogues (2'S)-2'-deoxy-2'-fluoro-Siodocytidine (FIAC) and (2'S)-2'-deoxy-2'-fluoro-S-iodouridine (FIAU) have potent antiviral activity for herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), cytomegalovirus (CMV) and varicella-zoster virus (VZV) (Lopez et el., 1980; Colacino and Lopez, 1983; Watanabe, 1983; Machida, 1986 ) though cytotoxicity of both compounds is relatively high in vitro and in vivo (Chou et al., 1981; Cheng et st., 1983) . Recently it has been disclosed that the novel nucleoside analogues; S-halogeno derivatives of (2'S)-2'-deoxy-2'-C-methylcytidine (SMOC) and (2'S)-2'-deoxy-2'-C-methyluridine (SMOU) have potent anti-HSV-1 activity (Awano et a/., 1994) . In this report, the S-halogenated congeners of SMOC and SMOU were examined for anti-HSV, VZV and CMV activity, and it was shown that both (2'S)-2'-deoxy-2'-C-methyl-S-iodocytidine (SMIC) and (2'S)-2'-deoxy-2'-C-methyl-S-iodouridine (SMIU) have potent anti-VZV activities.
The synthesis of the (2'S)-2'-C-methyldeoxy (SM) nucleoside compounds was reported previously (Awano et al., 1994) and the chemical structures of SM compounds as well as 2'-fluoro-S-iodoarabinofuranosylpyrimidine (FIAC and FIAU) are illustrated in Fig. 1 .
Lymphoid cell lines RPMI 8226 (kindly provided by Japan Cell Bank, Tokyo, Japan) were maintained in RPMI 1640 culture medium with 10% heat-inactivated fetal bovine serum (FBS), 300 Jlg mL-1 L-glutamine, 200 u mL-1 penicillin G and 200 Jlg mL-1 streptomycin. A human fibroblast cell line MRC-S was maintained in Eagle's minimal essential medium (MEM) with 10% heatinactivated FBS, with the same concentrations of L-glutamine and antibiotics. For virus infection, maintenance medium with 4% FBS was used. All cell lines were cultured at 3loC in S% CO 2 ,
The HSV-1 strains used in the experiments were: KOS, F, A4-3 which is aciclovir (ACV) resistant and Hangai, a clinical isolate. The HSV-2 strains were G. VZV strains, CaQu, Kanno-Kohmura (ACV resistant) and CMV A0169 were also used.
For this study a convenient method for examining anti-HSV-1 and anti-HSV-2 activity simultaneously was devised. This was based on the method of Takeuchi which was reported previously but is only able to assess anti-HSV-1 activity and not anti-HSV-2 activity (Takeuchi at al., 1991; Awano at al., 1994) . In the present method, we used RPMI 8226 cells, a human myeloma cell line instead of NC-37 cells (Kira at al., 1995a) . The viability of virus-infected and mock-infected cells was assessed by the MTT method (Pauwels at al., 1988) . Anti-HSV-2 activity was assessed using Sudo's method with MRC-5 cells (Sudo at al., 1994) . Anti-VZV and anti-CMV assays were carried out by the plaque reduction assay. VZV foci were counted by immuno-peroxidase staining (Saba at al., 1986) and the foci of CMV were counted after staining by crystal violet. In a previous report, anti-HSV-1 activity of s-hatoqenatec SM compounds were examined and 5MBU, SMIC and SMIU were shown to have anti-HSV-1 activity (Awano at al., 1994) . In the present study these compounds were reexamined for anti-HSV-1 activity using RPMI 8226 cells. As shown (Table 1) , s-bromo-and iodo-SM compounds had anti-HSV-1 activity but 5-f1uoro and chloro-SM compounds did not, i.e. 5MBC, 5MBU, SMIC and SMIU had anti-HSV-1 efficacy (Fig. 1, 1d, 2d , te, 2e). SM-cytidine analogues (SMBC and SMIC) were less inhibitory to HSV-1 when NC-37 cells were substituted for RPMI 8226 cells (Awano atel., 1994) . Similar variations in anti-HSV efficacy of adenine arabinoside (ara-A) in different host cells was reported previously (Takeuchi at al., 1991; Kira at al., 1995b) . SMIU (Fig. 1, 2e ), a congener of FIAU, was the most effective compound among the SM compounds examined (EC so =0.12!lg mL-1 ) ( Table 1 ). The anti-H8V-1 activity of SMIU was 1.5-fold less than FIAU; however, the cytotoxicity of SMIU in RPMI 8226 cells was 10-fold less than that of FIAU (Table. 1). A similar reduction of cytotoxicity was observed between SMIC and FIAC in which the base on the 2' position in the sugar moiety was changed from f1uoro to methyl. The antiviral activity of SM compounds against an ACVresistant HSV-1 strain, A4-3 and HSV-2 G using RPMI 8226 cells was also examined. None of the compounds had anti-A4-3 or anti-HSV-2 activity ( Table. 1 ). SMIC and SMIU were also ineffective against HSV-2 replication in the fibroblast cell line MRC-5 (Table 2) .
Four compounds which were effective against HSV-1 were examined for anti-VZV activity using the TK-positive strain (CaQu) and TK-negative strain (Kanno-Kohmura) (Shigeta at al., 1983) and for anti-CMV activity. All the SM compounds were active against TK-positive but not TKnegative VZV. 5MBC and 5MBU had higher ECsos (12-10.75!lg mL-1 ) , while the results for SMIC and SMIU were lower (0.95!lg mL-1 , 0.21!lg mL-1) than ACV against VZV. FIAC and FIAU showed 63-140-fold lower ECsos values against VZV than those of the 2'-methyl congeners (Table 2) . 5MBC, 5MBU, SMIC and SMIU were not inhibitory to CMV replication.
In this report it is confirmed that the SM nucleoside analogues SMIC and SMIU have potent anti-HSV-1 and -VZV activity in vitro but no activity against either HSV-2 or CMV. Among them SMIC and SMIU were less cytotoxic to RPMI 8226 and MRC-5 cells than the 2'··fluoro congeners, FIAC and FIAU. It is well known that FIAC and FIAU have anti-HSV-2 and CMV activities in vitro (Mar at al., 1984; Harada at al., 1987) . The change in the z'-poslnon of the sugar moiety from f1uoro to methyl most probably causes loss of binding of their monophosphate forms to the HSV-2 thymidine kinase (TK). HSV-2 TK is known to have lower activity for the phosphorylation of 5-bromovinyl deoxyuridine monophosphate than HSV-1 TK (Shimizu at , 1986) . 8M compounds have no inhibitoryactivity against TK-negative H8V-1, A4-3 or TK-negative VZV, Kanno-Kohmura. This suggests that 8M compounds require the virus-inducedTK in order to exert their antiviral activity. Four 8M pyrimidine nucleosides showed potent anti-VZV activity. Among them, 8MIC and 8MIU had 1.9-to 8.6-fold lower ECsos than ACV. FIAC and FIAU were reported to be potent anti-VZV and anti-CMV compounds (Machida, 1986; 8higeta et al., 1991) however, they appeared to show cytotoxicity for RPMI 8226 and MRC-5 cells. FIAU was reported to be severely toxic to humans when the compound was introduced for the therapy of hepatitis (Darby, 1994) . From the point of view of antiviral activity and cytotoxicity, substitution of the 2' position of the sugar moiety of FIAC and FIAU by methyl from fluoro reduced anti-H8V-2, anti-CMV activities and cytotoxicity but anti-H8V-1 and anti-VZV activities were retained. The anti-VZV activity of 8MIU and 8MIC was superior to that of ACV. 8MIU and 8MIC may be worthy of investigation for their therapeutic effects on VZV infection in man.
